Category: Antimicrobial Stewardship: Outcomes Assessment (clinical and economic)

Poster Session: Antimicrobial Stewardship: Outcomes Assessment (clinical and economic)

67 - Impact of a Pharmacist-Driven Collaborative Initiative on Staphylococcus aureus Bacteremia Management

The ePoster content is available to users who are logged in.<br><br>Please log in and then come back here to use this button.

Presenting Author(s)

Wesley D. Kufel

Clinical Associate Professor
Binghamton University School of Pharmacy Sciences
Binghamton, New York
Disclosure: Melinta (Research Grant or Support)Merck (Research Grant or Support)Theratechnologies, Inc. (Advisor or Review Panel member)

Co-Author(s)

KM

Keri A. Mastro

Pharmacy Student
Binghamton University School of Pharmacy and Pharmaceutical Sciences
Binghamton, New York
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
DW

Dongliang Wang

Associate Professor
SUNY Upstate Medical University
Syracuse, New York
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
JS

Jeffrey Steele

Clinical Pharmacy Specialist, Infectious Diseases
State University of New York Upstate University Hospital
Syracuse, NY
Disclosure: Paratek Pharmaceuticals (Advisor or Review Panel member)
SR

Scott W. Riddell

Director, Clinical Microbiology
State University of New York Upstate Medical University
Syracuse, New York
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
KP

Kristopher M. Paolino

Assistant Professor
State University of New York Upstate Medical University
Syracuse, New York
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
ST

Stephen J. Thomas

Division Chief, Infectious Diseases and Professor of Medicine and Microbiology & Immunology
Upstate Medical University
Syracuse, New York
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Background: Infectious diseases (ID) consultation has been associated with improved outcomes for Staphylococcus aureus bacteremia (SAB) largely by providing guidance to follow widely accepted standards. However, ID consultation may be delayed due to numerous factors. ID pharmacists may be able to facilitate timely and optimal management of SAB in collaboration with ID providers and microbiology. The primary outcome of this study was to evaluate the impact of a pharmacist-driven collaborative initiative for SAB.

Methods: This was a single-center, quasi-experimental study of patients with SAB before (8/1/16-7/31/17) and after (8/1/18-7/31/19) implementation of pharmacist-driven collaborative initiative for SAB management. After direct notification of SAB and penicillin-binding protein assay results from microbiology personnel, the ID pharmacist promptly contacted the primary team to facilitate ID consultation and identified opportunities to optimize treatment or diagnosis prior to consult. Recommendations were also collaboratively discussed with the ID consult service. Included patients were ≥18 years old with SAB. Excluded patients were < 18 years old, under palliative care or expired prior to S. aureus speciation, refused care against medical advice, pregnant, incarcerated, or had polymicrobial bacteremia.

Results: Ninety and 111 patients were included in the pre- and post-intervention cohort, respectively. Demographic data were similar between cohorts. Most SAB cases were community-acquired (72% vs 81%, p=0.137), complicated (83% vs 71%, p=0.059), and methicillin-susceptible (57% vs 65%, p=0.236). The most common sources were catheter (23%) and skin and soft tissue (30%) in pre- and post-intervention cohorts, respectively. Table 1 displays compliance with evidence-based SAB measures and clinical outcomes. Compliance with the SAB bundle was significantly higher in the post-intervention cohort (91% vs 50%, p< 0.001).Table 1. Compliance with Evidence-Based Staphylococcus aureus Bacteremia Management Bundle Elements and Clinical Outcomes

Conclusion: Increased compliance with evidence-based SAB recommendations decreased SAB duration, time to targeted antibiotics, and infection-related hospital length of stay after implementation of a pharmacist-driven collaborative initiative for SAB.